ResMed hits new highs as quarterly earnings leap
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Driven by buoyant sales of high-margin products, earnings per share hit US53¢ for the quarter, up from US42¢ a year earlier, which pushed the half-year earnings to $US1.02, up from US75¢.
Revenue for the quarter surged to $US376.5 million from $US332.7 million, reaching $US716.3 million for the half, up from $US647.5 million.
Revenue growth remained strongest in the US, rising 16 per cent in the quarter, well ahead of the 10 per cent growth recorded elsewhere. Despite challenging European conditions, Britain, France and Germany "delivered solid quarterly results", the chairman and chief executive, Mr Peter Farrell, told analysts.
The company said unit sales were growing at 4 per cent to 6 per cent in Europe, 6 per cent to 8 per cent in the US, and 8 per cent to 10 per cent in the Asia-Pacific region.
With the strong Australian dollar, production and assembly in Singapore now accounts for more than half of all units sold. This will eventually rise to an estimated 75 per cent, the company told analysts
on Friday.
Along with its production of high-end units in Australia, ResMed produces some low-end products such as masks in Malaysia.
The optimistic outlook, along with speculation that a weaker Australian dollar would give earnings a push, helped the shares hit new highs of $4.60 before easing slightly to finish at $4.58, up 30¢. ResMed's shares traded at $2.50 a year ago.
"These guys are industry best. They are great strategists," the Wilson HTM analyst Shane Storey said of the results. "It's had a great quarter, but the current quarter will be up against very strong year-earlier numbers," which may make growth comparisons difficult.
A dividend of US17¢ a share was declared, with holders of its Australian-listed scrip entitled to a dividend of US1.7¢ a share.
Call 1300 880 160
Start a chat
Schedule a call
